Fluorescence‐based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells
暂无分享,去创建一个
G. Mufti | K. Ramasamy | Y. Calle | J. Sturge | S. Schey | L. Macpherson | H. Khatun | M. Caley
[1] J. Waxman,et al. Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.
[2] Ove Andrén,et al. High‐throughput live‐cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts , 2011, International journal of cancer.
[3] J. Waxman,et al. Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.
[4] Luke A. Gilbert,et al. DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.
[5] K. Vandyke,et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] M. Piccart,et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts , 2010, BMC Cancer.
[7] Charles P. Lin,et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.
[8] K. Anderson,et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.
[9] S. Yaccoby,et al. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. , 2009, Cancer letters.
[10] H. Drexhage,et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. , 2009, Investigative ophthalmology & visual science.
[11] A. Zannettino,et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis , 2009, Leukemia.
[12] Charles P. Lin,et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.
[13] Shin-Yoon Kim,et al. Enhanced ex vivo expansion of human adipose tissue-derived mesenchymal stromal cells by fibroblast growth factor-2 and dexamethasone. , 2009, Tissue engineering. Part A.
[14] F. Saad. Src as a therapeutic target in men with prostate cancer and bone metastases , 2009, BJU international.
[15] Y. Furukawa,et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma , 2009, Oncogene.
[16] F. Gao,et al. Dasatinib in relapsed or plateau-phase multiple myeloma , 2009, Leukemia & lymphoma.
[17] P. Moreau,et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma , 2008, Haematologica.
[18] D. Ribatti,et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. , 2008, Blood.
[19] S. Taboga,et al. Cellular changes in the prostatic stroma of glucocorticoid-treated rats , 2008, Cell and Tissue Research.
[20] M. Dimopoulos,et al. Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.
[21] M. Copland,et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.
[22] Gareth E. Jones,et al. The leukocyte podosome. , 2006, European Journal of Cell Biology.
[23] R. Baron,et al. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function , 2005, Immunological reviews.
[24] A. Donnenberg,et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. , 2005, Blood.
[25] D. Bevan,et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK , 2004, British journal of haematology.
[26] K. Moriyama,et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. , 2004, Blood.
[27] A. Thrasher,et al. WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption. , 2004, Blood.
[28] Y. Ikeda,et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment , 2004, Pathology international.
[29] R. Weinstein,et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. , 2004, Endocrinology.
[30] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] P. Croucher,et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.
[32] B. Barlogie,et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity , 2002, British journal of haematology.
[33] M. Albrecht,et al. Effects of dexamethasone on proliferation of and fibronectin synthesis by human primary prostatic stromal cells in vitro , 2002, Andrologia.
[34] J. Michaeli,et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] Silvia Bernardini,et al. Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.
[36] Luigi Naldini,et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.
[37] D. Cutler,et al. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects , 1997, Biological Psychiatry.
[38] Lakkakorpi Pt,et al. Cytoskeletal changes in osteoclasts during the resorption cycle. , 1996 .
[39] P. Marchisio,et al. Characterization of bone marrow stromal cells from multiple myeloma. , 1994, Leukemia research.
[40] T. Yoneda,et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.
[41] D. Chauhan,et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.
[42] H. Väänänen,et al. Cytoskeletal changes in osteoclasts during the resorption cycle , 1996, Microscopy research and technique.
[43] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[44] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.